Meetings

Researchers and clinicians from the Mount Sinai Tisch Cancer Center will present new research at the 2026 Annual Meeting of the American Society of Clinical Oncology (ASCO), taking place Friday, May 29, through Tuesday, June 2, at McCormick Place in Chicago. 

Mount Sinai investigators will contribute to presentations across multiple cancer specialties, including hematologic malignancies, thoracic oncology, urothelial cancer, gynecologic oncology, translational science, and cancer care delivery. 

Mayo Clinic Comprehensive Cancer Center researchers will present more than 30 studies at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, highlighting advances in precision oncology, early cancer detection, artificial intelligence (AI) and personalized cancer care.

ASCO selects gentle yoga intervention for press program, as it showcases a non-drug solution that goes a step further than other symptom-management research. 

To help strengthen global collaboration and showcase innovative biotics research, The International Scientific Association for Probiotics and Prebiotics (ISAPP) is organizing a scientific symposium on October 6, 2026 in Tokyo, Japan in conjunction with its annual meeting. The event will bring together leading academic and industry experts in biotic science from North and South America, Europe, Australasia, and across Asia, all coming together for an exciting day of networking, discussion and knowledge-sharing.

CMCC and Politecnico di Milano will host the 4th International Conference on Carbon Dioxide Removal (CDR) on June 10–12, 2026, in Milan, Italy. The conference provides a platform for a vibrant global network of scholars and practitioners working to better understand the opportunities, risks, and governance challenges associated with carbon removal.

Explore how AI tools can revolutionize soil science, helping researchers better understand and adapt soils—and the systems they nurture—to a changing climate.

Researchers from the ECOG-ACRIN Cancer Research Group will present multiple discoveries at the American Society of Clinical Oncology Annual Meeting, including a late-breaking update from the STAMP study of pembrolizumab for Merkel cell carcinoma. Attendees can also expect primary results from studies on glioblastoma and non-small cell lung cancer, as well as exciting emerging approaches in precision oncology.

City of Hope researchers showcased new advances at ASCO 2026, highlighting progress in targeted therapies, microbiome science and blood cancers, with emerging findings in kidney, liver and prostate cancers underscoring a move toward more personalized, biology-driven treatment approaches.

Researchers from Mass General Brigham Cancer Institute will present research discoveries and outcomes from clinical trials in cancer at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, held May 29 – June 2, in Chicago 

 

ASCO brings together leading experts in clinical oncology to share the latest breakthroughs in cancer research, science and medicine. Presentations from Mass General Brigham Cancer Institute investigators include a study evaluating the outcomes of patients admitted to a dedicated oncology service within a multisite home hospital program; the results of a late-breaking plenary session on prostate cancer; efficacy and safety of a lung cancer drug; the efficacy of an app to support the psychosocial needs of patients with multiple myeloma; the creation of an electronic frailty index to inform risk ahead of CAR-T cell therapy treatments, and more.  

Below are a few highlights from this year’s presentations. All times are Central Time (CT).